Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.48 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13812270 | 0.91 | FLT3 (0.43) | TRPA1MAPK1FLT3MAPK3PRKCZ | |
| SCHEMBL13812109 | 0.89 | MAPK1 (0.42) | MAPK1MAPK3PRKCZLTA4H | |
| SCHEMBL13812273 | 0.87 | JAK2 (0.43) | PRKCZLTA4H | |
| SCHEMBL13811901 | 0.85 | PRKCZ (0.40) | PRKCZLTA4H | |
| SCHEMBL13877029 | 0.83 | TRPA1 (0.48) | TRPA1MAPK1FLT3MAP3K5 | |
| SCHEMBL13811895 | 0.83 | FLT3 (0.58) | TRPA1MAPK1FLT3MAP3K5MAPK3 | |
| SCHEMBL13812074 | 0.76 | MAPK1 (0.44) | MAPK1FLT3 | |
| SCHEMBL4171229 | 0.75 | FLT3 (0.44) | MAPK1FLT3 | |
| SCHEMBL4171226 | 0.75 | FLT3 (0.44) | MAPK1FLT3 | |
| SCHEMBL13812110 | 0.74 | FLT3 (0.43) | MAPK1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |